Navigation Links
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
Date:5/8/2009

- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data -

CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO(TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produces rapid improvements of both irritative and obstructive urinary symptoms that were sustained for 12 weeks, according to data published in the June issue of The Journal of Urology. RAPAFLO(TM) was developed and is manufactured by Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals.

In an analysis of data pooled from two Phase 3 studies, patients taking RAPAFLO(TM) demonstrated statistically significant symptom relief versus placebo within three to four days of starting treatment, and remained significant throughout the 12-week study period.

"The severity of urinary symptoms appears to depend in part on smooth muscle tone in the prostate and bladder neck, which is mediated by alpha 1A adrenoreceptors," said Leonard S. Marks, MD, author of the study and professor of urology at the Geffen School of Medicine, the University of California at Los Angeles. "The data indicate that RAPAFLO(TM) (silodosin) induces effective relaxation of the targeted prostatic muscle tissue, with a low incidence of vasodilatory and orthostatic effects. RAPAFLO(TM) (silodosin) is a fast acting, effective and safe treatment for the signs and symptoms associated with BPH."

BPH is the number one reason patients visit urologists and is characterized by urination problems, including decreased urine flow, more frequent urination and nocturia.

Clinical Trial Results

The new paper is a pooled analysis of two, 12-week, randomized, placebo-controlled, double-blind multi-center clinical trials involving 923 generally healthy men ages 50 or
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
2. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
3. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
4. USAID Provides $5M in Emergency Support as Swine Flu Spreads
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
6. Strativa Pharmaceuticals Provides Product Pipeline Update
7. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
8. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
9. Savient Provides Update on Pegloticase BLA
10. USAID Provides Malaria Assistance to Zimbabwe
11. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Anthem Blue Cross ... would have required them to obtain their medications by ... Watchdog and Whatley Kallas LLC.  The ... alleged that Blue Cross,s mandatory mail order program announced ... health and privacy. "This settlement brings to ...
(Date:5/23/2013)...  Texas, premier physician associations today announced the establishment ... they need to provide demonstrably better and more efficient ... "I am confident the Physician Services Organization ... Stephen L. Brotherton , MD, president of ... doctors are determined to make health care better ...
(Date:5/23/2013)... 23, 2013  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical ... infections, today announced that it has initiated dosing in ... once daily, oral therapy for the treatment of HCV ... and is designed to assess both the safety and ... first-in-class drug for the treatment of chronic HCV infections ...
Breaking Medicine Technology:Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... IRVINE, Calif., Jan. 5, 2011 Amp1, a ... off a tour of the Dallas-Fort Worth area with an ... Thunder game on Jan. 6th at the American Airlines Arena ... players will demonstrate how, with the help of modern high-tech ...
... Calif., Jan. 5, 2011 Ultra Clean Holdings, Inc. ... of critical subsystems, for the semiconductor capital equipment, medical ... Clarence Granger, Chairman and Chief Executive Officer, and Casey ... Needham Growth Conference. The presentation will take place at ...
Cached Medicine Technology:Amputees to Show off Stand-Up Basketball Skills in Dallas Mavericks Halftime Show Jan. 6 2
(Date:5/24/2013)... May 24, 2013 ResortQuest Real Estate® ... the Dayna Feher team at the firm’s Bethany Beach ... Delaware resorts her home in 1975. Her real estate ... in all aspects of the real estate business - ... past 12 years, a licensed sales associate. , ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- New research ... thoughts among people with insomnia. Every additional ... a 72 percent drop in the likelihood of ... researchers from the University of Pennsylvania. ... association between sleep duration and suicide risk," study ...
(Date:5/24/2013)... (HealthDay News) -- Drugs commonly used to treat glaucoma ... can interfere with vision, according to a new study. ... are used to reduce eye pressure, have already been ... eye color, the researchers said, suggesting that the new ... Doctors should be conservative when prescribing these drugs, ...
(Date:5/24/2013)... Area homeowners dreaming about owning a hot ... to choose from at factory-direct pricing during the Jacuzzi ... takes place at Emerald Pool and Patio in ... the industry's leading hot tub brand, scheduled the event as ... event will feature popular hot tub models at up to ...
(Date:5/24/2013)... myofibromatosis (IM)a disorder characterized by multiple tumors involving the ... according to researchers from the Icahn School of Medicine ... American Journal of Human Genetics , may lead to ... the only current treatment option is repeated surgical removal ... that develops in infancy or even in utero and ...
Breaking Medicine News(10 mins):Health News:Tammy Mushrush Joins ResortQuest Real Estate® and the Dayna Feher Team 2Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2
... tired, keeps having a high temperature even after recovering ... a differential blood count to try to determine the ... in the laboratory a routine procedure in medical ... white blood cells, are quantitatively and qualitatively assessed. The ...
... "This ESMO-symposium will allow bed-side oriented oncologists to ... All presentations will have a clear focus towards ... the major consequences that new developments in cancer ... Soria, Symposium Co-Chair The ESMO Symposium on ...
... structure known as the amygdala. It is the amygdala which ... not only triggers palpitations or nausea but can also cause ... known about the function of this part of the brain. ... and which of the countless neurons in the amygdaloid region ...
... (HealthDay News) -- Long-term use of vitamin E and C ... a new study finds. "An estimated 20.5 million persons ... of age-related cataract," wrote study author William G. Christen, of ... and colleagues, in a news release. Because oxidative damage ...
... , THURSDAY, Nov. 11 (HealthDay News) -- Many family caregivers ... care for their loved ones and experience high levels of ... their role, says a new study. "The care of ... are facing even greater challenges than other family caregivers," said ...
... Reporter , WEDNESDAY, Nov. 10 (HealthDay News) -- Offering ... offer some protection against the development of the antibodies associated ... of the disease, new research suggests. When Finnish ... 1 diabetes to receive either a regular infant formula, or ...
Cached Medicine News:Health News:Performing blood counts automatically 2Health News:Circuitry of fear identified 2Health News:Study Finds Vitamins E and C Don't Reduce Cataract Risk in Men 2Health News:Family Members Caring for Veterans Sacrifice Their Own Health, Jobs 2Health News:Family Members Caring for Veterans Sacrifice Their Own Health, Jobs 3Health News:Special Infant Formula Might Help Shield Babies from Type 1 Diabetes 2Health News:Special Infant Formula Might Help Shield Babies from Type 1 Diabetes 3Health News:Special Infant Formula Might Help Shield Babies from Type 1 Diabetes 4
Inquire...
... MicroAire Power Assisted Lipoplasty Device uses a 2-mm ... facilitate the movement of the cannula in tissue. ... with more fibrous tissue. That makes the lipoplasty ... will ease your mind to learn that the ...
... scfm/0-29.8 in.hg.@sea level. Incredibly quiet, yet very ... canister systems at one time eliminates the ... procedure. Standard canister set-up is for Abbott ... UL, c-UL and CE marks. Includes a ...
... cohesive is a new term being used today to ... more liquid fill that may have been used in ... new science, this is not new technology cohesive ... describe the sticking together nature of the gel. All ...
Medicine Products: